Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Bexagliflozin
Placebo for Bexagliflozin
Glimepiride
Placebo for Glimepiride
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of T2DM
- Currently taking metformin or taking metformin and one additional oral medication for diabetes
- Body Mass Index (BMI) ≤ 45 kg/m2
- Stable dose of blood pressure or cholesterol medications (if applicable) for at least 30 days
Exclusion Criteria:
- Hypersensitivity or other contraindication to the safe use of sulfonylurea or glimepiride
- Diagnosis of type 1 diabetes mellitus or maturity-onset/diabetes of the young
- Current use of injected therapy for treatment of diabetes (insulin or GLP-1 receptor agonist therapy) or thiazolidinedione class drugs
- History of genitourinary tract infections
- Evidence of abnormal liver function
- Myocardial infarction, stroke or hospitalization for heart failure within 3 months of screening
- Prior kidney transplant or evidence of kidney problems
- Pregnant or nursing
Sites / Locations
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site 2
- Research Site 2
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site 2
- Research Site 2
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site 2
- Research Site
- Research Site 2
- Research Site 3
- Research Site
- Research Site 2
- Research Site
- Research Site 2
- Research Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Bexagliflozin
Glimepiride
Arm Description
Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for glimepiride daily for the duration of the study.
Subjects will receive a glimepiride capsule, 2, 4 or 6 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.
Outcomes
Primary Outcome Measures
Change From Baseline in HbA1c at Week 60
The primary objective is to demonstrate that bexagliflozin is non-inferior to glimepiride by evaluating the treatment effect on HbA1c reduction at week 60 in subjects whose T2DM is inadequately controlled by metformin. The least square mean (LSM) change from baseline to Week 60 was analyzed using a mixed model repeated measures (MMRM) analysis of covariance model (ANCOVA).
Secondary Outcome Measures
Change From Baseline in Body Weight at Week 60 for Subjects With Baseline BMI ≥ 25 kg/m2
Least squares (LS) mean treatment difference between the bexagliflozin group and placebo group in the change of body weight in subjects with baseline BMI ≥ 25 kg/m2 at week 60 is analyzed using ANCOVA.
Change From Baseline in Systolic Blood Pressure (SBP) at Week 60 for Subjects With Baseline SBP ≥ 140 mmHg
Least squares (LS) mean treatment difference between the bexagliflozin group and placebo group in the change of SBP in subjects with baseline SBP ≥ 140 mmHg at week 60 is analyzed using ANCOVA.
Difference in Proportion of Subjects With ≥ 1 Severe or Documented Symptomatic Hypoglycemia Events Over 96 Weeks
The difference in proportion of subjects with ≥ 1 severe or documented symptomatic hypoglycemia events in the bexagliflozin group compared with glimepiride group over 96 weeks is analyzed using a logistic regression model. The full model included region, baseline HbA1c value, background treatment status (metformin or metformin + OHA), eGFR at baseline ≥ 90 or < 90 mL min 1 per 1.73 m2), treatment as a fixed effect covariate.
Superiority of Bexagliflozin Over Glimepiride in HbA1c Reduction at Week 60.
Superiority of bexagliflozin over glimepiride in HbA1c reduction from baseline to week 60 will be declared if the upper bound of 95% CI is less than 0.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02769481
Brief Title
Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Official Title
A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of Bexagliflozin Versus Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
August 15, 2016 (Actual)
Primary Completion Date
June 14, 2019 (Actual)
Study Completion Date
June 14, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Theracos
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to investigate the effect of bexagliflozin compared to glimepiride as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
Detailed Description
Approximately 420 subjects with inadequately controlled T2DM on metformin will be recruited from North America and Europe. Subjects will be randomly assigned to receive bexagliflozin tablets, 20 mg, or glimepiride capsules, 2, 4 or 6 mg, in a ratio of 1:1 once daily for 96 weeks. Subjects will continue to take metformin for the duration of the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
426 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Bexagliflozin
Arm Type
Active Comparator
Arm Description
Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for glimepiride daily for the duration of the study.
Arm Title
Glimepiride
Arm Type
Active Comparator
Arm Description
Subjects will receive a glimepiride capsule, 2, 4 or 6 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.
Intervention Type
Drug
Intervention Name(s)
Bexagliflozin
Other Intervention Name(s)
EGT0001442
Intervention Description
20 mg, tablet
Intervention Type
Drug
Intervention Name(s)
Placebo for Bexagliflozin
Intervention Description
inactive tablet to match active comparator bexagliflozin
Intervention Type
Drug
Intervention Name(s)
Glimepiride
Intervention Description
2, 4 or 6 mg, capsule
Intervention Type
Drug
Intervention Name(s)
Placebo for Glimepiride
Intervention Description
inactive capsules to match active comparator glimepiride
Primary Outcome Measure Information:
Title
Change From Baseline in HbA1c at Week 60
Description
The primary objective is to demonstrate that bexagliflozin is non-inferior to glimepiride by evaluating the treatment effect on HbA1c reduction at week 60 in subjects whose T2DM is inadequately controlled by metformin. The least square mean (LSM) change from baseline to Week 60 was analyzed using a mixed model repeated measures (MMRM) analysis of covariance model (ANCOVA).
Time Frame
Baseline and Week 60
Secondary Outcome Measure Information:
Title
Change From Baseline in Body Weight at Week 60 for Subjects With Baseline BMI ≥ 25 kg/m2
Description
Least squares (LS) mean treatment difference between the bexagliflozin group and placebo group in the change of body weight in subjects with baseline BMI ≥ 25 kg/m2 at week 60 is analyzed using ANCOVA.
Time Frame
Baseline and 60 weeks
Title
Change From Baseline in Systolic Blood Pressure (SBP) at Week 60 for Subjects With Baseline SBP ≥ 140 mmHg
Description
Least squares (LS) mean treatment difference between the bexagliflozin group and placebo group in the change of SBP in subjects with baseline SBP ≥ 140 mmHg at week 60 is analyzed using ANCOVA.
Time Frame
Baseline and 60 weeks
Title
Difference in Proportion of Subjects With ≥ 1 Severe or Documented Symptomatic Hypoglycemia Events Over 96 Weeks
Description
The difference in proportion of subjects with ≥ 1 severe or documented symptomatic hypoglycemia events in the bexagliflozin group compared with glimepiride group over 96 weeks is analyzed using a logistic regression model. The full model included region, baseline HbA1c value, background treatment status (metformin or metformin + OHA), eGFR at baseline ≥ 90 or < 90 mL min 1 per 1.73 m2), treatment as a fixed effect covariate.
Time Frame
During the 96 week treatment period
Title
Superiority of Bexagliflozin Over Glimepiride in HbA1c Reduction at Week 60.
Description
Superiority of bexagliflozin over glimepiride in HbA1c reduction from baseline to week 60 will be declared if the upper bound of 95% CI is less than 0.
Time Frame
Baseline to Week 60
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of T2DM
Currently taking metformin or taking metformin and one additional oral medication for diabetes
Body Mass Index (BMI) ≤ 45 kg/m2
Stable dose of blood pressure or cholesterol medications (if applicable) for at least 30 days
Exclusion Criteria:
Hypersensitivity or other contraindication to the safe use of sulfonylurea or glimepiride
Diagnosis of type 1 diabetes mellitus or maturity-onset/diabetes of the young
Current use of injected therapy for treatment of diabetes (insulin or GLP-1 receptor agonist therapy) or thiazolidinedione class drugs
History of genitourinary tract infections
Evidence of abnormal liver function
Myocardial infarction, stroke or hospitalization for heart failure within 3 months of screening
Prior kidney transplant or evidence of kidney problems
Pregnant or nursing
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
J. Paul Lock, MD
Organizational Affiliation
Theracos Sub, LLC
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35205
Country
United States
Facility Name
Research Site
City
Huntington Park
State/Province
California
ZIP/Postal Code
90255
Country
United States
Facility Name
Research Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
Research Site
City
San Carlos
State/Province
California
ZIP/Postal Code
94070
Country
United States
Facility Name
Research Site
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33012
Country
United States
Facility Name
Research Site
City
Miami Lakes
State/Province
Florida
ZIP/Postal Code
33016
Country
United States
Facility Name
Research Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
Research Site
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33401
Country
United States
Facility Name
Research Site
City
Calabash
State/Province
North Carolina
ZIP/Postal Code
28467
Country
United States
Facility Name
Research Site
City
Morehead City
State/Province
North Carolina
ZIP/Postal Code
28557
Country
United States
Facility Name
Research Site
City
Magnolia
State/Province
Texas
ZIP/Postal Code
77355
Country
United States
Facility Name
Research Site
City
Aschaffenburg
ZIP/Postal Code
63739
Country
Germany
Facility Name
Research Site
City
Essen
ZIP/Postal Code
45277
Country
Germany
Facility Name
Research Site 2
City
Essen
ZIP/Postal Code
45355
Country
Germany
Facility Name
Research Site 2
City
Hamburg
ZIP/Postal Code
21073
Country
Germany
Facility Name
Research Site
City
Hamburg
ZIP/Postal Code
22607
Country
Germany
Facility Name
Research Site
City
Heidelberg
ZIP/Postal Code
69115
Country
Germany
Facility Name
Research Site
City
Magdeburg
ZIP/Postal Code
39120
Country
Germany
Facility Name
Research Site
City
Wangen
ZIP/Postal Code
88239
Country
Germany
Facility Name
Research Site
City
Bochnia
ZIP/Postal Code
32-700
Country
Poland
Facility Name
Research Site
City
Bydgoszcz
ZIP/Postal Code
85-312
Country
Poland
Facility Name
Research Site
City
Kraków
ZIP/Postal Code
30-015
Country
Poland
Facility Name
Research Site 2
City
Kraków
ZIP/Postal Code
31-011
Country
Poland
Facility Name
Research Site 2
City
Lublin
ZIP/Postal Code
20-064
Country
Poland
Facility Name
Research Site
City
Lublin
ZIP/Postal Code
20-362
Country
Poland
Facility Name
Research Site
City
Olsztyn
ZIP/Postal Code
10-117
Country
Poland
Facility Name
Research Site
City
Poznań
ZIP/Postal Code
61-655
Country
Poland
Facility Name
Research Site
City
Puławy
ZIP/Postal Code
24-100
Country
Poland
Facility Name
Research Site
City
Staszów
ZIP/Postal Code
28-200
Country
Poland
Facility Name
Research Site
City
Swarzędz
ZIP/Postal Code
62-020
Country
Poland
Facility Name
Research Site
City
Toruń
ZIP/Postal Code
87-100
Country
Poland
Facility Name
Research Site
City
Warszawa
ZIP/Postal Code
00-660
Country
Poland
Facility Name
Research Site
City
Zamość
ZIP/Postal Code
22-400
Country
Poland
Facility Name
Research Site
City
Łódź
ZIP/Postal Code
90-242
Country
Poland
Facility Name
Research Site
City
Świdnik
ZIP/Postal Code
21-040
Country
Poland
Facility Name
Research Site
City
Alicante
Country
Spain
Facility Name
Research Site 2
City
Barcelona
Country
Spain
Facility Name
Research Site
City
Barcelona
Country
Spain
Facility Name
Research Site 2
City
Madrid
Country
Spain
Facility Name
Research Site 3
City
Madrid
Country
Spain
Facility Name
Research Site
City
Madrid
Country
Spain
Facility Name
Research Site 2
City
Malaga
Country
Spain
Facility Name
Research Site
City
Malaga
Country
Spain
Facility Name
Research Site 2
City
Oviedo
Country
Spain
Facility Name
Research Site
City
Valencia
Country
Spain
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
We'll reach out to this number within 24 hrs